All In Biotech

Drug Trial Radar · NCT07172347

Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo

A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 31, 2025

Primary completion

Aug 30, 2027

Study completion Aug 30, 2027

Sponsor

Sponsor type
Industry
First posted
Sep 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study

Conditions

  • Non-segmental Vitiligo

Interventions

  • VC005 tabletsDrug

    VC005 groups repeat administration for 52 weeks

  • VC005 Tablets PlaceboDrug

    VC005 Placebo groups repeat administration for 52 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in facial vitiligo area score index (F-VASI) relative to baseline at week 24Time frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Peking University People's Hospital

    Beijing, Beijng, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.